

DAFTAR PUSTAKA

- Abubakar, M., Sung, H., Devi, B.C.R., Guida, J., Tang, T.S., Pfeiffer, R.M. 2018. Breast Cancer Risk Factors, Survival and recurrence, and Tumor molecular Subtype: Analysis of 3012 Women from An Indigenous Asian Population. *Breast Cancer Research*, 20: 1-14.
- Aebi, S., Davitson, T., Gruber, G., Cardoso, F. 2011. Primary Breast Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment a. *Annals of Oncology*, 22:12-24.
- Adam, J. M. F., Purnamasari, D. 2014. Diabetes Mellitus Gestasional. Dalam: Setiati, S., Alwi, I., Sudoyo, A. W., Simadibrata, M., Setiyohadi, B., Syam, A. F. (Ed): *Buku Ajar Ilmu Penyakit Dalam Edisi Ke VI*, pp: 2428-33. Pusat Penerbitan Ilmu Penyakit Dalam, Jakarta.
- Ahn, S., Lee, Y. S., Chun, Y. H, Lim, K, S., Kim, W., Lee, J. L. 2012. Predictive Factors of Bacteraemia in Low Risk Patients with Febrile Neutropenia. *Emerg Med*, 29: 715-719.
- American Cancer Society. 2017. Breast Cancer Risk Factors You Cannot Change. Available from : <https://www.cancer.org/cancer/breast-cancer/risk-and-prevention/breastcancer-risk-factors-you-cannot-change.html>
- Ando, S., Gesolimo, L., Panza, S., Giordano, C., Bonofiglio, D, Marone., Catalano, S. 2018. Obesity, Leptin and Breast Cancer: Epidemiological Evidence and Proposed Mechanism. *Cancers*, 11 (62): 1-27.
- Artac M, Bozcuk H, Afacan B, Ozdogan M, Samur M. 2008. The Impact of Waist-to-hip Ratio on Clinical Outcomes in Metastatic Breast Cancer Patients Treated with Aromatase Inhibitors. *The Breast*, 17: 418-422.
- Atalay, G., Dirix, L., Biganzoli, L., Beex, L., Nooij, M., Cameron, D., Lohrisch, C., Cufer, T., Lobelle, J. P., Mattiaci, M, R., Piccart, M., Paridaens R. 2004. The Effect of Exemestane on Serum Lipid Profile in Postmenopausal Women with Metastatic Breast Cancer: A Companion Study to EORTC Trial 10951, 'Randomized Phase II Study in First Line Hormonal Treatment for Metastatic Breast Cancer with Exemestane or Tamoxifen in Postmenopausal Patients. *Annals of Oncology*, 15: 211-217.

- Balsan, G. A., Veira, J., Oliveira, A. 2015. Relationship Between Adiponectin, Obesity and Insulin Resistance', *Revista da Associação Médica Brasileira*, 61(1): 72–80.
- Biglia, N., Peano, E., Sgandura, P., Moggio, G., Pecchio, S., Maggiorotto, F., Sismondi, P. 2013. Body Mass Index (BMI) and Breast Cancer: Impact on Tumor Histopathologic Features, Cancer Subtypes and Recurrence Rate in Pre and Postmenopausal Women. *Gynecological Endocrinology*, 29(3): 263-267.
- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., Jemal, A. 2018. Global Cancer statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *Ca Cancer J Clin*, 00: 1-31.
- Brochu-Gaudreau, K., Rehfedt, C., Blouin, R. 2010. Adiponectin Action from Head to Toe', *Endocrine*, 37(1): 11–32.
- Burstein, H. J. 2005. The Distinctive Nature of HER2-Positive Breast Cancer. *N Engl J med*, 353:1652–1654.
- Buzdar, A. U., Robertson, J. F. R., Eirmann, W., Nabholz, J., M. 2002. An Overview of the Pharmacology and Pharmacokinetics of the Newer Generation Aromatase Inhibitors Anastrozole, Letrozole, and Exemestane. *American Cancer Society*, 95: 2006-2016.
- Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I. T., Zackrisson, S., Senkus, E. 2019. Early Breast Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. *Annals of Oncology*, 30: 1194-1220.
- Chae, Y. K., Valsecchi, M. E., Kim J, Bianchi, A. L., Khemasuwan, D., Desai, A., Tester, W. 2011. Reduced Risk of Breast Cancer Recurrence in Patients Using ACE Inhibitors, ARBs, and/ or Statins. *Cancer Investigation*, 29: 585-593.
- Champ, C. E., Volek, J. S., Siglin, J., Jin, L., Simone, N. L. 2012. Weight Gain, Metabolic Syndrome, and Breast Cancer recurrence: Are Dietary Recommendation Supported by the Data. *Int J Breast Cancer*, 2012: 1-9.
- Chang, S.C., Yang, W.C. 2016. Hyperglycemia, Tumorigenesis, and Chronic Inflammation. *J Crit Care*, 108: 146-153.

Chelbowski, R. T., Tiernan, A. M., Wende, J. W., Manson, J. E., Aragaki, A. K., Rohan, T., Ipp, E., Kaklamani, V. G., Vitolins, M., Wallace, R., Gunter, M., Phillips, L. S., Strickler, H., Margolis, K., Euhus, D. M. 2012. Diabetes, Metformin, and Breast Cancer in Postmenopausal Women. *J Clin Oncol*, 30: 2844-52.

Cirillo, D. Rachiglio, A. M., La Montagna, R., Giordano, A., Normanno, N. 2008. Leptin Signaling in Breast cancer: An Overview. *Journal of Cellular Biochemistry*, 105(40): 956-964.

Coleman, R. Letrozole versus Observation in Patients with Newly Diagnosed Uterine Leiomyosarkoma. *MD Anderson Cancer Center*, 1-18.

Conceicao, M., Oliveira, B., Costa-Silva, R., R., Andrane, D. B., Borges, U. S., Tavares, C. B., Borges, R. S., Silva, J. M., Silva, B. B. 2016. Use of Anastrozole in the Chemoprevention and Treatment of Breast Cancer: A Literature Review. *Rev Assoc Bras*, 63 (4): 371-378.

Dahlan, M. S. 2010. Menentukan Rumus Besar Sampel. Dahlan, M. S (Eds). *Besar Sampel dan Cara Pengambilan Sampel*. Jakarta: Salemba Medika. pp: 19-21.

Dai, X., Chen, A. and Bai, Z. 2015. Integrative Investigation on Breast Cancer in ER, PR and HER2-defined Subgroups Using mRNA and miRNA Expression Profiling. *Scientific Reports*. 4(6566): 1-10.

Dai, X, Xiang, L., Li, T. 2016. Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes, *Journal of Cancer*, 7(710): 1281–1294.

DeCicco, P. D., Catani, M. V., Gasperi, V., Sibilano, M., Quaglietta, M., Savini, I. 2019. Nutrition and Breast Cancer: A Literature Review on Prevention, Treatment and Recurrence. *Nutrients*, 11: 4-28.

Di Sibio, A., Abriata, G., Buffa, R., Viniegra, M., Forman, D., Siera, M. S. 2016. Lyon: Internasional Agency for Research on Cancer 2016: Etiology of breast cancer (C50) in Central and South America. Available from: http://www-dep.iarc.fr/CSU_resources.htm

Edge, S. B., Compton, C. C. 2010. The American Joint Committee on Cancer: the 7th edition of the AJCC Cancer Staging Manual and the Future of TNM. *Ann Surg Oncol*, 17(6):1471-4.

Elisaf, M. S., Bairaktari, E. Th., Nicolaidis, C., Kakaidi, B., Tzallas, C. S., Katsaraki, A., Pavlidis, N. A. 2001. Effect of Letrozole on the Lipid Profile in Postmenopausal Women with Breast Cancer. *European Journal of Cancer*, 37: 1510-1513.

- Elliott, K. M., Dent, J., Stanczyk, F. S., Woodley, R. C., Purohit, A., Palmieri, C. 2014. Effects of Aromatase Inhibitors and Body Mass Index on Steroid Hormone Levels in Woman with Early and Advance Breast Cancer. *British Journal of Surgery*, 101: 939-948.
- Ellis, E. O., Schnitt, S. J., Sastre-Garau, X., Bussolati, G., Tavassoli, F. A., Eusebi, V. 2003. The breast. In Tavasolli, Devilee (Eds). *Pathology and genetic of tumours of the breast and female genital organs / WHO classification of tumours*. Washington: IARC Press; p.10, 34 – 6.
- Ewertz, M., Ewertz, M., Jensen, M. B., Gunnarsdottir, K. A., Cold, S., Cold, S.. 2011. Effect of Obesity on Prognosis After Early-stage Breast Cancer. *J Clin Oncol*, 29: 25-31.
- Fattah, M. 2006. Sindroma Metabolik dan Penanda Baru Disfungsi Endotel: Asimetrik Dimetil Arginin (ADMA) dan High Sensitivity C-Reactive Protein (Hs-CRP). *Forum Diagnosticum*; (1).
- Folkerd, E. J., Dixon, J. M., Renshaw, L., A'Hern, R. P., Dowset, M. 2012. Suppression of Plasma Estrogen Levels by Letrozole and Anastrozole is Related to Body Mass Indeks in Patients with Breast Cancer. *J Clin Oncol*, 30: 2977-2980.
- Francini, G., Petrioli, R., Montagnani, A., Cadirni, A., Campagna, S., Francini, E., Gonelli, S. 2006. Exemestane after Tamoxifen as Adjuvant Hormonal Therapy in Postmenopausal Women with Breast Cancer: Effect on Body Composition and Lipids. *British Journal of Cancer*, 95: 153-158.
- Fryk, E., Olauson, J., Mossberg, K., Strindberg, L., Schmelz, M., Brogen, H., et al. 2021. Hyperinsulinemia and Insulin resistance in the Obese may Develop as Part of A Homeostatic Response to Elevated Free Fatty Acids: A Mechanistic Case Control and A Population Based Cohort Study. *J Ebiom*, 65: 1-15.
- Gezgen, G., Roach, E. C., Kizilarlanoglu, I., Petekaya, I., Altundag, K. 2012. Metabolic Syndrome and Breast Cancer: an Overview. *Journal of BUON*, 17: 223-229.
- Gibb, F. W., Horner, N. Z. M., Faqehi, A. M. M., Upreti, R., Livingstone, D. E., McInnes, K. J., Andrew, R., Walker, B. R. 2016. Aromatase Inhibisi Reduces Insulin Sensitivity in Healthy Men. *J Clin Endocrinol Metab*, 4146: 1-9.

- Gibb, F. W., Dixon, M. J., Clarke, C., Homer, N. Z., Faqehi, A. M. M., Andrew, R., Walker, B. R. 2019. Higher Insulin Resistance and Adiposity in Postmenopausal Women with Breast Cancer Treated with Aromatase Inhibitor. *J Clin Endocrinol Metab*, 104 (9): 3670-3678.
- Gonzalez, R.R., Cherfils, S., Escobar, M., Yoo, J.H., Carino, C., Styer, A.K., Sullivan, B.T., Sakamoto, H., Olawaiye, A., Serikawa, T., Lynch, M.P., Rueda. B.R. 2006. Leptin Signaling Promotes the Growth of Mammary Tumors and Increases the Expression of Vascular Endothelial Growth Factor (VEGF) and Its Receptor Type Two (VEGF-R2). *J Biol Chem* 281(36):26320–26328.
- Goss, P. E., Hadji, P., Subar, M., Abreu, P., Thomsen, T., Banke-Bochita, J. 2007. Effect of Steroidal and Nonsteroidal Aromatase Inhibitors on Markers of Bone Turnover in Healthy Postmenopausal Women. *Breast Cancer Research*, 9: 1-14.
- Goodwin, P. J. 2013. Obesity and Endocrine Therapy: Host Factors and Breast Cancer. *The Breast*, 22: 544-547.
- Guiu, S., Michiels, S., Andre, F., Cortes, J., Denkert, C., Di Leo, A., Hernessi, B. T., Sorlie, T., Sotiriou, C., Turner, N., Van de Viver, M., Viale, G., Rels-Filho, J. S. 2010. Molecular Subclasses of Breast Cancer: How Do We Define Them? The IMPAKT 2012 Working Group Statement. *Annals of Oncology*, 23: 2997-3006.
- Hadji, P., Kauka, A., Bauer, T., Tams, J., Hasenburg, A., Kieback, D. G. 2012. Effects of Exemestane and Tamoxifen on Hormone Levels within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) Trial: Result of a German Substudy. *CLIMACTERIC*, 15: 460-466.
- Han, H., Guo, W., Shi, W., Yu, Y., Zhang, Y., Ye, XF., He, J. 2016. Hypertension and Breast Cancer Risk: A Systematic review and Meta-Analysis. *Scientific Report*, 1-9.
- Hamed. E.A., Zakhary, M.M., Maximous, D.W. 2012. Apoptosis, angiogenesis, inflammation, and oxidative stress: basic interactions in patients with early and metastatic breast cancer. *J Cancer Res Clin Oncol* 138(6):999–1009.
- Haque, R., Shi, J., Schottinger, J. E., Chung, J., Avila, C., Amundsen, B., Xu, X., Barac, A., Chelbowski, R. T. 2016. Cardiovascular Disease After Aromatase Inhibitor Use. *JAMA Oncol*, 2 (12): 1590-1597.
- He, D. X., Ma, X. 2016. Clinical Utility of Letrozole in The Treatment of Breast Cancer: A Chinese Perspective. *Onco Targets and Therapy*, 9: 1077-1084.

Iliopoulos, D., Hirsch, H.A., Wang, G., Struhl, K. 2011. Inducible Formation of Breast Cancer Stem Cells and Their Dynamic Equilibrium with Non-stem Cancer Cells Via IL6 Secretion. *Proc Natl Acad Sci U S A* 108(4):1397–1402.

Internasional Agency for Research on Cancer (IARC) / WHO. 2018. GLOBOCAN 2018: Latest global cancer data: Cancer burden rises to 18.1 million new cases and 9.6 million cancer deaths in 2018. Available from: https://www.iacr.fr.pr263_E

Iwata, H., Masuda, N., Ohno, S., Rai, Y., Sato, Y., Ohzumi S., Hashigaki, S., Hiraoka, M., Morimoto, T., Sasano, H., Saeki, T., Noguchi, S. 2013. A Randomized, Double-blind, Controlled Study of Exemestane versus Anastrozole for the First-line Treatment of Postmenopausal Japanese Women with Hormone-receptor-positive Advanced Breast Cancer. *Breast Cancer Res Treat*, 139: 441-451.

Jee, S.H., Kim, H.J., Lee J. 2005. Obesity, Insulin Resistance and Cancer Risk. *Yonsei Medical Journal*, 46(4): 449-455.

Judson, G. M., Capizi, T. F., Mertens, W. C. Does Switching from Tamoxifen to an Aromatase Inhibitor Result in Weight Change in Postmenopausal Breast Cancer Patients. *The Open Breast Cancer Journal*, 2: 66-70.

Kalluri, R dan Weinberg, R. A. 2009. The Basics of Epithelial-mesenchymal Transition. *J Clin Invest* 119(6):1420–1428.

Karihtala, P., Jaaskelainen, A., Roininen, N., Jukkola, A. 2020. Prognostic Factor in Metastatic Breast Cancer: A Prospective Single-Centre Cohort Study in a Finnish University Hospital. *BMJ Open*, 1-6.

Kawai, M., Tomotaki, A., Miyata, H., Iwamoto, T., Niikura, N., Anan, K., Hayashi, N., Aogi, K., Ishida, T., Masuoka, H., Iijima, K., Masuda, S., Tsugawa, K., Kinoshita, T., Nakamura, S., Tokuda, Y. 2016. Body Mass Index and Survival after Diagnosis of Invasive Breast Cancer: A Study Based on The Japanese National Clinical Database-Breast Cancer Registry. *Cancer Med*, 5: 1328-40.

Key, T. 2002. Endogenous Sex Hormones and Breast Cancer in Postmenopausal Women: Reanalysis of Nine Prospective Studies. *J Natl Cancer*, 94 (8): 606-616.

- Kim, J. H., Kwon, H., Lee, J. W., Kim, H. J., Lee, S. B., Park, H. S., Sohn, G., Lee, Y., Koh, B. S., Yu, J. H., Son, B. H., Ahn, S. H. 2015. Metformin Increases Survival in Hormone Receptor-positive, HER2-positive Breast Cancer Patients with Diabetes. *Breast Cancer Research*, 17(64): 1-14
- Kittaneh, M., Gluck, S. 2011. Exemestane in the Adjuvant Treatment of Breast Cancer in Postmenopausal Women. *Breast Cancer: Basic and Clinical Research*, 5: 209-226.
- Komite Nasional Penanggulangan Kanker (KPKN). 2017. Panduan Nasional Penanganan Kanker Payudara. Kementerian Kesehatan Republik Indonesia.
- Konefka, E. S., Kunikowska, O. E., Dziadziuszko, R., Jassem, J. 2006. Exacerbation of Diabetes Related to Exemestane Treatment. *Acta Oncologica*, 47 (60): 1167-1169.
- Kozakowski, J., Gietka-Czemel, M., Lesczynska, D., Majos, A. 2017. Obesity in Menopause- Our Negligence or an Unfortunate Inevitability. *Menopause Rev*, 16 (2): 61-65.
- Kwan, M.L., Chen, W.Y., Kroenke, C.H., Weltzien, E.K., Beasley, M.J., Nechuta, S.J., Poole, E.M., Lu, W., Holmes, M.D., Queensberry Jr, C.P., Pierce, J.P., Shu, X.O., Cnaan, B.J. 2012. Prediagnosis Body Mass Index and Survival After Breast Cancer in the After Breast Cancer Pooling Project. *Breast Cancer Res Treat*, 132(2): 729-39.
- Kyvernitakis, I., Albert, U. S., Winarno, M. K., Hars, O., Hadji, P. 2014. Effect of Anastrozole on Hormone Level in Postmenopausal Women with Early Breast Cancer. *CLIMACTERIC*, 17: 1-6.
- Lanari, C., Lamb, C. A., Fabris, V. T., Helguero, L. A., Soldati, R., Bottino, M. C, *et al.* 2009. The MPA mouse breast cancer model: evidence for a role of progesterone receptors in breast cancer. *Endocrine-related cancer* ; 16: 333-50
- Litton, J. K., Bevers, T. B., Arun, K. B. 2012. Exemestane in the Prevention Setting. *Ther Adv Med Oncol*, 4 (3): 107-112.
- Loannides, S. J., Barlow, P. L., Elwood, J. M. 2014. Effect of Obesity on Aromatase Inhibitor Efficacy in Postmenopausal, Hormon Receptor-positive Breast Cancer: A Systematic Review. *Breast Cancer Res Treat*, 147: 237-248.

- Lonning, P. E., Benjamin, P. H., Dowset, M. 2014. Relationship of Body Mass Indeks with Aromatisation and Plasma and Tissue Oestrogen Levels in Postmenopausal Breast Cancer Patients Treated with Aromatase. *European Journal of Cancer*, 50: 1055-1064.
- Lumachi, F., Brunello, A., Maruzzo, M., Basso, U., Basso, S. 2013. Treatment of Estrogen Receptor-positive Breast Cancer. *Current medicinal chemistry*, 20(5), 596-604.
- Malhotra, G. K., Zhao, X., Band, H., Band, V. 2010. Histological, Molecular and Functional Subtype of Breast Cancer. *Cancer Biology and Therapy*, 10(10): 955-960.
- Miller, W. R. 2005. Background and Development of Aromatase Inhibitors. In Furr, B. J. A (Eds) : *Aromatase Inhibitors*. Germany : Birkhauser. pp : 1-22.
- Miller, W. R., Barlett, J., Brodie, A. M. H., Brueggemeier, R. W., Salle, E., Lonning, P. E., Llombart, A., Maass, N., Maudelonde, T., Sasano, H., Goss, P. E. 2008. Aromatase Inhibitors: Are They Differences Between Steroidal and Nonsteroidal Aromatase Inhibitors and Do They Matter. *The Oncologist*, 13: 829-837.
- Moon, H. G., Han, W., Noh, D. Y. 2009. Underweight and Breast Cancer Recurrence and Death: A Report from the Korean Breast Cancer Society. *J Clin Oncol*, 27: 5899-905.
- Morigi, C. 2014. Highlights of the 16th St Gallen International Breast Cancer Conference, Vienna, Austria, 20-23 March 2019: Personalised Treatment for Patients with Early Breast Cancer. *ECancer*, 924: 1-17.
- Mouridsen, H., Bhatnagar, A. 2014. Letrozole in the Treatment of Breast Cancer. *Expert Opin. Pharmacother*, 6(8): 1389-1399.
- Nichols, H. B., Dietz, A. T., Egan, K. M., Ernstoff, L. T., Holmes, M. D., Bersch, A. J., Holick, C. N., Hampton, J. M., Stampfer, M. J., Willet, W. C., Newcomb, P. A. 2009. Body Mass Indeks Before and After Breast Cancer Diagnosis: Association with All-cause, Breast Cancer, and Cardiovascular Disease Mortality. *Cancer Epidemiol Biomarkers Prev*, 18 (5): 1403-1409.
- Niraula, S., Ocana, A., Ennis, M., Goodwin, P., 2012. Body Size and Breast Cancer Prognosis in Relation to Hormone Receptor and Menopausal Status: A Meta Analysis. *Breast Cancer Res Treat*, 134; 769-81.

NCCN National Comprehensive Cancer Network. 2019. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Available from : www.nccn.org/patients

Nuttall, F. Q. 2015. Body Mass Index. *Nutrition Today*, 50(3): 117-128.

Nyrop, K. A., Deal, A. M., Lee, J. T., Muss, H. B., Choi, S. K., Dixon, S., Wheles, A., Carey L. A., Shachar, S. S. 2017. Weight Changes in Postmenopausal Breast Cancer Survivors Over 2 Years of Endocrine Therapy: A Retrospective Chart review. *Breast Cancer Res Treat*, 1-14.

Pantschenko, A. G., Pushkar, I., Anderson, K. H., Wang, Y., Miller, L. J., Kurtzman, S. H., Kreutzer, D. L. 2003. The Interleukin-1 Family of Cytokines and Receptors in Human Breast Cancer: Implications for Tumor Progression. *Int J Oncol* 23(2):269–284.

Ping, Z., Xia, N., Zhang, H., Deng. 2020. The Metabolic Syndrome Is a Risk Factor for Breast Cancer: A Systematic review and meta-Analysis. *Obes Facts*, 13: 384-396.

Placido, S. D., Gallo, C., Laurentis, M. D., Bisagni, G., Arpino, G., Sarobba, M. G., Ricarardi, F., Russo, A., Mastro, L. D., Cagoni, A. A., Cognetti, F., Gori, S., Foglietta, J., Frassoldati, A., Amorosa, D., Laudadio, L., Morsetti, L., Montemurro, F., Verusio, C., Bernardo, a., Larusso, V., Gravina, A., Moretti, G., Lauria, R., Lai, A., Mocerino, C., Rizzo, S., Nuzzo, F., Carlini, P., Peronne, F. 2018. Metabolic Syndrome and Breast Cancer: an Overview. *Lancet Oncol*, 18: 1-12.

Poloz, Y., Stambolic, V. 2015. Obesity and Cancer, A Case for Insulin Signaling. *Cell Death and Disease*, 6: 1-11.

Redig, A. j., Munshi, H. G. 2010. Care of the Cancer Survivor: Metabolic Syndrome Following Hormone-modifying Therapy. *Am J Med*, 123 (1): 1-10.

Rossi, E., Morabito, A., Di Rella, F., Esposito, G., Gravina, A., Labonisa, V., Landi, G., Nuzzo, F., Pacilio., C., Maio., D. E., Maio, D. M., Piccilo, M. C., Feo, D. G., D’Aiuto, G., Botti, G., Chiodini, P., Gello, C., Perrone, F., Matteis, A. 2009. Endocrine Effects of Adjuvant Letrozole Compared with Tamoxifen in Hormone-Responsive Postmenopausal Patients with Early Breast Cancer: The HOBEO Trial. *J Clin Oncol*, 27: 3192-3197.

Sawada, S., Sato, K., Kusuhara, M., Ayaqri, M., Yonemura, A., Tamaki, K., Hiraide, H., Mochizuki, H., Ohsuzu, F., 2005. Effect of Anastrozole and Tamoxifen on Lipid Metabolism in Japanese Postmenopausal Women with Early Breast Cancer. *Acta Oncologia*, 44: 134-141.

- Schneider, R., Barakat, A., Pippen, J., Osborne, C. 2014. Aromatase Inhibitors in the Treatment of Breast Cancer in Post-menopausal Female Patients: An Update. *Breast Cancer: Targets and Therapy*, 3: 113-125.
- Sendur, M. A. N., Aksoy, S., Zengin, N., Altundang, K. 2012. Efficacy of Adjuvant Inhibitor in Hormone Receptor-positive Postmenopausal Breast Cancer Patients According to the Body mass Index. *British Journal of Cancer*, 107: 1815-1819.
- Sendur, M. A. N., Aksoy, S., Zengin, N., Altundag, K. 2013. Comparative Efficacy Study of 5-year Letrozole or Anastrozole in Postmenopausal Hormone Receptor-positive Early Breast Cancer. *Journal of BUON*, 18 (4): 838-844.
- Sendur, M. A. N., Aksoy, S., Akinci, M. B., Ozdemir, N., Dede, D, S., Altundag, K., Zengin, N., Yalcin, B. 2015. Role of Obesity on the Efficacy of Exemestane plus Ovarian Suppression in Hormone Receptor-positive Premenopausal Breast Cancer. *Future Oncol*, 11 (6): 905-907.
- Senkus, E., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rutgers, E., Zackrisson, S., Cardoso, F. 2015. Primary Breast Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. *Annals of oncology*, 26(suppl_5):8-30.
- Sestak, I., Howell, A., Harvie, MN., Forbes, JF. 2012. Weight Change Associated with Anastrozole and Tamoxifen Treatment in Postmenopausal Women with or at high risk of Developing Breast Cancer. *Breast Cancer Research and Treatment*. 134(2): 727-734.
- Sinicrope, F. A., Danneberg, A. J. 2010. Obesity and Breast Cancer Prognosis: Weight of the Evidence. *American Society of Clinical Oncology*, 29 (1): 25-31.
- Smith, I., Yardley, D., Burris, H. A., Boer, R. D., Amadori, D., McIntyre, K., Eirjetsen, B., Gnani, M., Jonat, W., Pritchard, K. I., Dowsett, M., Hart, L., Poggio, S., Comarella, L., Salomon, H., Wamil, B., O'Shaughnessy, J. 2017. Sendur, M. A. N., Aksoy, S., Akinci, M. B., Ozdemir, N., Dede, D, S., Altundag, K., Zengin, N., Yalcin, B. 2015. Role of Obesity on the Efficacy of Exemestane plus Ovarian Suppression in Hormone Receptor-positive Premenopausal Breast Cancer. *Future Oncol*, 11 (6): 905-907.

Smith, I., Yardley, D., Burris, H., De Boer, R., Amadori D., McIntyre, K., Ejlersten, B., Gnant, M., Jonat, W., Pritchard, I. K., Dowsett, M. D., Hart, L., Poggio, S., Comarella, L., Salomon, H., Wamil, B., O,Shaughnessy, J. Comparative Efficacy and Safety Adjuvant Letrozole versus Anastrozole in Postmenopausal Patients with Hormone Receptor-positive, Node-positive Early Breast Cancer: Final Result of the Randomized Phase III Femara versus Anastrozole Clinical Evaluation (FACE) Trial. *J Clin Oncol*, 36: 1041-1048.

Stoddart, B.M.H., DeCensi, A., Sahasrabudhe, V. V. 2017. Repurposing Metformin for the Prevention of Cancer and Cancer Recurrence. *Diabetologia*, 1-9.

Surmacz, E. dan Otvos, L. 2015. Molecular Targeting of Obesity Pathways in Cancer. *Hormone Molecular Biology and Clinical Investigation*, 22(2): 53–62

Sun, L., Zhu, Y., Qian, Q., Tang, L. 2018. Body Mass indeks and Prognosis of Breast cancer: An Analysis by Menstruation status when Breast Cancer Diagnosis. *Medicine*, 97 (26): 1-9.

Takada, M., Saji, S., Masuda, N., Kuroi, K., Sato., N., Takei, H., Yamamoto, Y., Ohno, S., Yamashita, H., Hisamatsu, K., Aogi, K., Iwata, H., Ueno, T., Sasano, H., Toi, M. 2012. Relationship between Body Mass Indeks and Preoperative Treatment Response to Aromatase Inhibitor Exemestane in Postmenopausal Patients with Primary Breast Cancer. *The Breast*, 21: 40-45.

Tan, B. K. T., Lim, G. H., Tan, P. H., Yap, Y. S., Sean, Y. W., Madhukumar, P., Wee, O. K., Chia, K. Seng. 2015. Differences in Survival of Women with Breast Cancer from Different Ethnic Groups in Singapore- A Population Based Cancer Registry Study and an Institutional Based Review. *J Cancer Biol*, 3(3): 1-12.

Tanko, L., Bruun, J., Alexandersen, P., Bagger, Y. Z., Richelsen, B., Christiansen, C., Larsen, P. J. 2004. Novel Associations Between Bioavailable Estradiol and Adipokines in Elderly Women with Different Phenotypes of Obesity: Implications for Atherogenesis. *Circulation*, 110(15): 2246–2252.

Trisnawati, I., 2008. *Kadar Adiponektin Pada Orang Obes Dengan dan Tanpa Dislipidemia Aterogenik* [thesis]. Univ. Gadjah Mada, Yogyakarta

Wasan, K. M., Goss, P. E., Pritchard, P. H., Sheperd, L., Palmer, M. J., Liu, S., Tu, D., Ingle, J. N., Health, M., DeAengelis, D., Perez, E. A. 2005. The Influence of Letrozole on Serum Lipid Concentrations in Postmenopausal Women with Primary Breast Cancer who Have Complete 5 Years of Adjuvant Tamoxifen (NCIC CTG MA.17L). *Annals of Oncology*, 16: 707-715.

Weigelt, B., Baehner, F. L. and Reis-Filho, J. S. 2009. The Contribution of Gene Expression Profiling to Breast Cancer Classification, Prognostication and Prediction: A Retrospective of the Last Decade. *The Journal of Pathology*.220: 263-280.

WHO Expert Consultation. 2004. Appropriate Body-mass Index for Asian Populations and Its Implications for Policy and Intervention Strategies. *Lancet*. 2004;363(9403):157–16.

World Medical Association. 2017. WMA Declaration of Helsinki Ethical Principles Medical Research Involving Human Subjects. Available from : <https://www.wma.net/policiest-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research—involving-human-subjects.htm>

Yager, J. D., Davidson, N. E. 2006. Estrogen Carcinogenesis in Breast Cancer. *N Engl J Med*, 354: 270-282.

Yerushalmi, R., Dong, B., Chapman, J. W., Goss, P. E., Polak, M. N., Burnell, M. J., Levine, M. N., Bramwell, V. H. C., Pritchard, K. I., Whelan, T. J., Ingle, J. N., Shelpherd, L. E., Parulekar, W. R., Han, L., Ding, K., Gelmon, K. A. 2017. Impact of Baseline BMI and Weight Change in CCTG Adjuvant Breast Cancer Trials. *Annals of Oncology*, 28: 1560-1568.

Zekri, J., Farag, K., Allithy, A. 2017. Obesity and Outcome of Post-menopausal Women Receiving Adjuvant letrozole for Breast Cancer. *Ecancer*, 12 (821): 1-10.

Zohre, M., Hamid, S. 2019. Epidemiological Characteristic of and Risk Factors for Breast Cancer in the World. *Breast Cancer Targets and Therapy*, 11: 151-164.